| AE | Adverse Event |
| ARR | Absolute Risk Reduction |
| CI | Confidence Interval |
| COPD | Chronic Obstructive Pulmonary Disease |
| DEMO | Demographic/administrative file |
| DRUG | Drug information file |
| EBGM | Empirical Bayesian Geometric Mean |
| FAERS | FDA Adverse Event Reporting System |
| FEV1 | Forced Expiratory Volume in 1 s |
| FF | Fluticasone Furoate |
| IC | Information Component |
| ICS | Inhaled Corticosteroid |
| IQR | Inter Quartile Range |
| LABA | Long-Acting Beta2 Agonist |
| LAMA | Long-Acting Muscarinic Antagonist |
| MedDRA | Medical Dictionary for Regulatory Activities |
| PRR | Proportional Reporting Ratio |
| PT | Preferred Term |
| PS | Primary Suspect |
| REAC | Reaction file |
| ROR | Reporting Odds Ratio |
| SOC | System Organ Class |
| SGRQ | St. George’s Respiratory Questionnaire |
| TTO | Time-To-Onset |
| UMEC | Umeclidinium |
| VI | Vilanterol |